A Cost-Effective De-escalation Strategy in Advanced Melanoma

Response-adapted de-escalation of ipilimumab in patients with advanced melanoma has the potential to lower healthcare costs.

Related Keywords

Germany ,New York ,United States ,Munich ,Bayern ,University Hospital ,Jeffrey Weber ,Joseph Skitzki ,Wolfgang Kunz ,Roswell Park Comprehensive Cancer Center ,Langone Health ,Perlmutter Cancer Center ,Medscape Medical ,New York City ,Melanoma ,Malignant Melanoma ,Skin Cancer ,Alignant Skin Neoplasm ,Biologic Therapy ,Immunotherapy ,Health Care Economics ,Conomics ,Social Determinants Of Health ,Cancer ,Alignant Neoplasia ,Arcinoma ,Computed Tomography ,It ,Clinical Research ,Clinical Trials ,Linical Studies ,Health Care Costs ,Health Expenditures ,Healthcare And Medical Technology ,Ealth And Medical Tech ,Ealth And Med Tech ,Meal ,